20 stories about Copaxone
קור שולץ קאר שולץ מנכ"ל טבע מסיבת עיתונאים בורסה לניירות ערך

Teva stock plummets by double figures on back of U.S. government kickback lawsuit

18.08.20|CTech and Sophie Shulman
The Department of Justice accuses Israeli drugmaker of using kickbacks to boost sales of its multiple sclerosis drug Copaxone, as well as causing the submission of false claims to Medicare
קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
default image

Senior Teva R&D Executive Joins Cannabis Company Cannassure

18.08.19|Tzally Greenberg
Yafit Stark was responsible for Teva’s clinical development program during the development of flagship drug Copaxone
מפעל תרופות טבע

Credit Line and Bonds: Teva's Financial Catch

12.08.19|Uri Tal-Tene
At first glance, Teva’s second quarter reports provided little cause for drama. The small print reveals a very different story
אתר טבע כפר סבא

Former Execs, Directors, to Pay Teva $50 Million for Part in Bribery Damages

25.07.19|Tomer Ganon
A recently reached settlement will see the Israeli drugmaker receive compensation for the fines it paid U.S. and Israeli authorities after being charged with conspiracy to violate the anti-bribery provisions of the Foreign Corrupt Practices Act in 2016
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Where is Kåre Schultz?

17.07.19|Sophie Shulman
The Danish CEO was drafted to save Teva straight off the successful turnaround of pharma company Lundbeck. Since then, the Israeli company’s market cap dropped by 66%, but Schultz has stayed mum
חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
נסיעת בכורה של רכבת מהירה מ ירושלים ל תל אביב

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19|Lilach Baumer
The clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
מנכ"ל טבע החדש קור שולץ 2

Teva to Close 11 More Manufacturing Facilities in 2019

14.02.19|Lilach Baumer
The drugmaker published its fourth quarter and annual reports Wednesday, dropping almost 8% on NYSE after forecasting a steep cut in profits for 2019
קאר שולץ מנכל טבע

Teva Falls in Pre-Market Following Low-Profit Forecasts for 2019

13.02.19|Lilach Baumer
The drugmaker forecasts revenues of $17 billion to 17.4 billion for 2019, much lower than analyst expectations
מנכ"ל טבע החדש קור שולץ 2

Copaxone Profit will Continue to Fall, But Teva is Set to Double Down on Biosimilars

08.01.19|Lilach Baumer and Hezi Sternlicht
Speaking at J.P. Morgan’s Healthcare Conference on Monday, CEO Kåre Schultz said he expects the U.S. generic market to stabilize in 2019
ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
מנכ"ל טבע החדש קור שולץ 2

Teva Shut Down New York, Washington Offices, Says CEO

23.02.18|Dror Reich
In a meeting with investors in Israel, CEO Kåre Schultz said the Washington offices were used mainly by lobbyists, for which Teva has no further need
הפגנה מפגינים פיטורים טבע אשדוד

Teva Executive Calls Company’s Fourth Quarter “Fairly Good”

11.02.18|Dror Reich
Following the publication of the company's reports, S&P Global downgraded Teva’s corporate credit rating to junk bonds
אינפו טבע מחירי תרופות גנריות Teva generic drug prices

The Crucial Piece of Information Teva Overlooked

24.12.17|Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
default image

Former Teva Executive One Step Closer to Bringing Copaxone Rival to Market

31.10.17|Lilach Baumer
Mapi Pharma announced a successful phase II clinical trial for its Copaxone equivalent GA Depot
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone